Latently Infected Cell Activation: A Way to Reduce the Size of the HIV Reservoir?

Bulletin of Mathematical Biology

Volumn 74, Issue 7, 2012, Pages 1651-1672

  Forde, Jonathan ^a   Volpe, Joseph M ^b   Ciupe, Stanca M ^c  

^a Hobart and William Smith College   (United States)

^b Virginia Tech ^*

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

HIV; Immune activation therapy; Latent reservoir; Mathematical model

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; BIOLOGICAL MODEL; CD4+ T LYMPHOCYTE; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; STATISTICS; VIROLOGY; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84861740708     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-012-9729-x     Document Type: Article

References (60)

1. Archin, N. M., & Margolis, D. M. (2006). Attacking latent HIV provirus: from mechanism to therapeutic strategies. Curr. Opin. HIV & AIDS, 1, 134-140.
2. Archin, N. M., Eron, J. J., Palmer, S., Hartmann-Duff, A., Martinson, J. A., Wiegand, A., Bandarenko, N., Schmitz, J. L., Bosch, R. J., Landay, A. L., Coffin, J. M., & Margolis, D. M. (2008). Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS, 22, 1131-1135.
3. Blankson, J. N., Persaud, D., & Siliciano, R. F. (2002). The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med., 53(1), 557-593.
4. Blas-Garcia, A., Esplugues, J. V., & Apostolova, N. (2011). Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity. Curr. Med. Chem., 18(14), 2186-2195.
5. Burnett, J. C., Lim, K., Calafi, A., Rossi, J. J., Schaffer, D. V., & Arkin, A. P. (2010). Combinatorial latency reactivation for HIV-1 subtypes and variants. J. Virol., 84(12), 5958-5974.
6. Callaway, D. S., & Perelson, A. S. (2002). HIV-1 infection and low steady state viral loads. Bull. Math. Biol., 64(1), 29-64.
7. Chomont, N., El-Far, M., Ancuta, P., Trautmann, L., Procopio, F. A., Yassine-Diab, B., Boucher, G., Boulassel, M.-R., Ghattas, G., Brenchley, J. M., Schacker, T. W., Hill, B. J., Douek, D. C., Routy, J.-P., Haddad, E. K., & Sékaly, R.-P. (2009). HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med., 15, 893-900.
8. Chomont, N., DaFonseca, S., Vandergeeten, C., Ancuta, P., & Sékaly, R.-P. (2011). Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr. Opin. HIV & AIDS, 6, 30-36.
9. Chun, T. W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., Kuo, Y. H., Brookmeyer, R., Zeiger, M. A., Barditch-Crovo, P., & Siliciano, R. F. (1997a). Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 387, 183-188.
10. Chun, T. W., Stuyver, L., Mizell, S. B., Ehler, L. A., Mican, J. A. M., Baseler, M., Lloyd, A. L., Nowak, M. A., & Fauci, A. S. (1997b). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA, 94(24), 13193-13197.
11. Chun, T. W., Engel, D., Berrey, M. M., Shea, T., Corey, L., & Fauci, A. S. (1998). Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA, 95(15), 8869-8873.
12. Chun, T. W., Engel, D., Mizell, S. B., Hallahan, C. W., Fischette, M., Park, S., Davey, R. T. Jr., Dybul, M., Kovacs, J. A., Metcalf, J. A., Mican, J. M., Berrey, M. M., Corey, L., Lane, H. C., & Fauci, A. S. (1999). Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med., 5(6), 651-655.
13. Chun, T. W., Justement, J. S., Moir, S., Hallahan, C. W., Maenza, J., Mullins, J. I., Collier, A. C., Corey, L., & Fauci, A. S. (2007). Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis., 195, 1762-1764.
14. Contreras, X., Schweneker, M., Chen, C.-S., McCune, J. M., Deeks, S. G., Martin, J., & Peterlin, B. M. (2009). Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem., 284, 6782-6789.
15. d'Arminio Monforte, A., Lepri, A., & Rezza, G. (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS, 14, 499-507.
16. Davey, R. T., Chaitt, D. G., Piscitelli, S. C., Wells, M., Kovacs, J. A., Walker, R. E., Falloon, J., Polis, M. A., Metcalf, J. A., Masur, H., Fyfe, G., & Lane, H. C. (1997). Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis., 175(4), 781-789.
17. Di Mascio, M., Dornadula, G., Zhang, H., Sullivan, J., Xu, Y., Kulkosky, J., Pomerantz, R. J., & Perelson, A. S. (2003). In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to < 5 copies per milliliter, with a half-life of 6 months. J. Virol., 77, 2271-2275.
18. Di Mascio, M., Percus, J. K., Percus, O. E., Markowitz, M., Ho, D. D., & Perelson, A. S. (2005). Duration of an intermittent episode of viremia. Bull. Math. Biol., 67, 885-900.
19. Dornadula, G., Zhang, H., VanUitert, B., Stern, J., Livornese, L., Ingerman, M. J., Witek, J., Kedanis, R. J., Natkin, J., DeSimone, J., & Pomerantz, R. J. (1999). Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA J. Am. Med. Assoc., 282(17), 1627-1632.
20. Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D. D., Richman, D. D., & Siliciano, R. F. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 278(5341), 1295-1300.
21. Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., Quinn, T. C., Chaisson, R. E., Rosenberg, E., Walker, B., Gange, S., Gallant, J., & Siliciano, R. F. (1999). Latent infection of CD4+ T cells provides a mechanism for life long persistence of HIV-1, even in patients on effective combination therapy. Nat. Med., 5, 512-517.
22. Fraser, C., Ferguson, N. M., Ghani, A. C., Prinsa, J. M., Langea, J. M. A., Goudsmitb, J., Anderson, R. M., & de Wolf, F. (2000). Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS, 14, 659-669.
23. Freed, E. O., & Martin, M. A. (2007). HIVs and their replication. In D. M. Knipe & P. M. Howley (eds.), Field's Virology, pp. 2107-2186. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
24. Geeraert, L., Kraus, G., & Pomerantz, R. J. (2008). Hide-and-seek: The challenge of viral persistence in HIV-1 infection. Annu. Rev. Med., 59(1), 487-501.
25. Gunthard, H. F., Havlir, D. V., Fiscus, S., Zhang, Z.-Q., Eron, J., Mellors, J., Gulick, R., Frost, S. D. W., Brown, A. J. L., Schleif, W., Valentine, F., Jonas, L., Meibohm, A., Ignacio, C. C., Isaacs, R., Gamagami, R., Emini, E., Haase, A., Richman, D. D., & Wong, J. K. (2001). Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J. Infect. Dis., 183(9), 1318-1327.
26. Harrigan, P. R., Whaley, M., & Montaner, J. S. (1999). Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS, 13, F59-F62.
27. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 373, 123-126.
28. Hockett, R. D., Kilby, J. M., Derdeyn, C. A., Saag, M. S., Sillers, M., Squires, K., Chiz, S., Nowak, M. A., Shaw, G. M., & Bucy, R. P. (1999). Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J. Exp. Med., 17, 1545-1554.
29. Hunt, P. W., Brenchley, J., Sinclair, E., McCune, J. M., Roland, M., Shafer, K. P., Hsue, P., Emu, B., Krone, M., Lampiris, H., Douek, D., Martin, J. N., & Deeks, S. G. (2008). Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis., 197(1), 126-133.
30. Jones, L. E., & Perelson, A. S. (2007). Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J. Acquir. Immune Defic. Syndr., 45, 483-493.
31. Kaufmann, G. R., Bloch, M., Zaunders, J. J., Smith, D., & Cooper, D. A. (2000). Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS, 14(8), 959-969.
32. Kim, H., & Perelson, A. S. (2006). Viral and latent reservoir persistence in HIV-1 infected patients on therapy. PLoS Comput. Biol., 2, e135.
33. Kovochich, M., Marsden, M. D., & Zack, J. A. (2011). Activation of latent HIV using drug-loaded nanoparticles. PLoS ONE, 6, e18270.
34. Lehrman, G., Hogue, I. B., Palmer, S., Jennings, C., Spina, C. A., Wiegand, A., Landay, A. L., Coombs, R. W., Richman, D. D., Mellors, J. W., Coffin, J. M., Bosch, R. J., & Margolis, D. M. (2005). Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. The Lancet, 366(9485), 549-555.
35. Lok, J. J., Bosch, R. J., Benson, C. A., Collier, A. C., Robbins, G. K., Shafer, R. W., Hughes, M. D., & ALLRT team (2010). Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS, 24(12), 1867-1876.
36. Margolis, D. M. (2010). Mechanisms of HIV latency: an emerging picture of complexity. Curr. HIV/AIDS Rep., 7, 37-43.
37. Markowitz, M., Louie, M., Hurley, A., Sun, E., Di Mascio, M., Perelson, A. S., & Ho, D. D. (2003). A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol., 77, 5037-5038.
38. Mellberg, T., Gonzalez, V., Lindkvist, A., Eden, A., Sonnerborg, A., Sandberg, J., Svennerholm, B., & Gisslen, M. (2011). Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV. AIDS Res. Ther., 8(1), 21.
39. Nettles, R. E., Kieffer, T. L., Kwon, P., Monie, D., Han, Y., Parsons, T., Cofrancesco, J. Jr., Gallant, J. E., Quinn, T. C., Jackson, B., Flexner, C., Carson, K., Ray, S., Persaud, D., & Siliciano, R. F. (2005). Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA J. Am. Med. Assoc., 293(7), 817-829.
40. Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G. J., Brun, S. C., Kempf, D. J., Mellors, J. W., Coffin, J. M., & King, M. S. (2008). Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA, 105(10), 3879-3884.
41. Perelson, A. S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., & Ho, D. D. (1997). Decay characteristics of HIV-1-infected compartments during combination therapy. Nature, 387, 188-191.
42. Ramratnam, B., Bonhoeffer, S., Binley, J., Hurley, A., Zhang, L., Mittler, J. E., Markowitz, M., Moore, J. P., Perelson, A. S., & Ho, D. D. (1999). Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet, 354, 1782-1785.
43. Rong, L., & Perelson, A. S. (2009a). Modeling HIV persistence, the latent reservoir, and viral blips. J. Theor. Biol., 260(2), 308-331.
44. Rong, L., & Perelson, A. S. (2009b). Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math. Biosci., 217(1), 77-87. Mathematical Models of Inflammation.
45. Rong, L., & Perelson, A. S. (2009c). Modeling latently infected cell activation: Viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput. Biol., 5, e1000533.
46. Sachsenberg, N., Perelson, A. S., Yerly, S., Schockmel, G. A., Leduc, D., Hirschel, B., & Perrin, L. (1998). Turnover of CD4 and CD8 T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J. Exp. Med., 187, 1295-1303.
47. Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004). Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu. Rev. Immunol., 22, 745-763.
48. Sedaghat, A. R., Siciliano, R. F., & Wilke, C. O. (2008). Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect. Dis., 8, 1-14.
49. Shen, L., & Siliciano, R. F. (2008). Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J. Allergy Clin. Immunol., 122, 22-28.
50. Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., & Siliciano, R. F. (2003). Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med., 9, 727-728.
51. Siliciano, J. D., Lai, J., Callender, M., Pitt, E., Zhang, H., Margolick, J. B., Gallant, J. E., Cofrancesco, J. Jr., Moore, R. D., Gange, S. J., & Siliciano, R. F. (2007). Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis., 195, 833-836.
52. Simon, V., & Ho, D. D. (2003). HIV-1 dynamics in vivo: implications for therapy. Nat. Rev., Microbiol., 1, 181-190.
53. Smith, R., & Aggarwala, B. (2009). Can the viral reservoir of latently infected CD4 T cells be eradicated with antiretroviral HIV drugs? J. Math. Biol., 59, 697-715.
54. Stafford, M. A., Corey, L., Cao, Y., Daar, E. S., Ho, D. D., & Perelson, A. S. (2000). Modeling plasma virus concentration during primary HIV infection. J. Theor. Biol., 203, 285.
55. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castillo-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med., 355, 1018-1028.
56. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S., & Shaw, G. M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 373, 117-122.
57. Wolschendorf, F., Duverger, A., Jones, J., Wagner, F. H., Huff, J., Benjamin, W. H., Saag, M. S., Niederweis, M., & Kutsch, O. (2010). Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J. Virol., 84(17), 8712-8720.
58. Yang, H. C., Shen, L., Siciliano, R. F., & Pomerantz, J. L. (2009). Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proceedings of the National Academy of Science (USA) (pp. 6321-6325).
59. Yates, A., Stark, J., Klein, N., Antia, R., & Callard, R. (2007). Understanding the slow depletion of memory CD4+ T cells in HIV infection. PLoS Med., 4, e177.
60. Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S., Talal, A., Racz, P., Perelson, A. S., Korber, B. T., Markowitz, M., & Ho, D. D. (1999). Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med., 340, 1605-1613.